Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosis. (2nd November 2021)

• Record Type: Journal Article
• Authors: Thompson, Alexander G; Oeckl, Patrick; Feneberg, Emily; Bowser, Robert; Otto, Markus; Fischer, Roman; Kessler, Benedikt; Turner, Martin R
• Is Part Of: Expert review of proteomics. Volume 18:Number 11(2021)
• Page Start: 977
• Page End: 994
• Publication Date: 2021-11-02
• Subjects: Amyotrophic lateral sclerosis -- biomarkers -- neurodegeneration -- proteomics -- cerebrospinal fluid -- TDP-43 -- SOD1 -- C9orf72; Proteins -- Biotechnology -- Periodicals; Proteomics -- Periodicals; 572.6
• DOI: 10.1080/14789450.2021.2004890
• Languages: English
• ISSNs: 1478-9450

Abstract

ABSTRACT: Introduction: Proteomic analysis has contributed significantly to the study of the neurodegenerative disease amyotrophic lateral sclerosis (ALS). It has helped to define the pathological change common to nearly all cases, namely intracellular aggregates of phosphorylated TDP-43, shifting the focus of pathogenesis in ALS toward RNA biology. Proteomics has also uniquely underpinned the delineation of disease mechanisms in model systems and has been central to recent advances in human ALS biomarker development. Areas covered: The contribution of proteomics to understanding the cellular pathological changes, disease mechanisms, and biomarker development in ALS are covered. Expert opinion: Proteomics has delivered unique insights into the pathogenesis of ALS and advanced the goal of objective measurements of disease activity to improve therapeutic trials. Further developments in sensitivity and quantification are expected, with application to the presymptomatic phase of human disease offering the hope of prevention strategies.